Search
Viridian Therapeutics Inc
VRDNAdd to Watchlist
21.430USD
-0.690-3.12%
Close 09-23 16:00（ET）
2.37BMarket Cap
LossP/E TTM
Viridian Therapeutics Inc (VRDN) Stock Price Target & Forecast
Analyst Rating
Based on 17 analysts giving stock ratings to Viridian Therapeutics Inc in the past month.
Buy
6 Strong Buy
11 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
36.200USD+63.65%
VRDN Analyst Recommendation Trends
In the current month, VRDN has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. VRDN average Analyst price target in the last month is 36.200.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
6
6
6
6
6
7
7
7
11
11
11
10
10
10
10
10
0
0
0
1
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17
17
17
17
18
19
19
19
VRDN Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, VRDN EPS is projected to reach -0.907 in FY2026Q3, following reported EPS of -1.178 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.07
-1.09
-1.03
-0.91
-0.89
Actual
-1.27
-1.03
-1.18
--
--
Surprise
-19.15%
+6.22%
-14.48%
--
--
FAQs
What is Viridian Therapeutics Inc's expected revenue for the next quarter?
Viridian Therapeutics Inc's expected revenue is 10.65M.
What is Viridian Therapeutics Inc's price target?
Analysts forecast that Viridian Therapeutics Inc's price target is USD 36.20, with the highest forecast at USD 50.00 and the lowest forecast at USD 22.00.
How have Viridian Therapeutics IncVRDN's recent earnings per share performed?
The market expectation was USD -1.18, while Viridian Therapeutics IncVRDN's earnings per share (EPS) for the previous quarter was USD -1.03. EPS for the next quarter is expected at USD -0.91.
What is the analyst rating for Viridian Therapeutics Inc?
Based on the ratings of Viridian Therapeutics Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.